Loading clinical trials...
Loading clinical trials...
Evaluating the Impact of Alpha Ketoglutarate (AKG), a Geroprotector, in Reducing Morbidity and Improving Patient-Centred Outcomes After Coronary Artery Bypass Grafting Surgery in Resilient and Poorly-Resilient Patients: A Double-Blind Placebo-Controlled Clinical Trial
Conditions
Interventions
Alpha-ketoglutarate
Placebo
Locations
2
Singapore
National University Hospital
Singapore, Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
Start Date
June 11, 2024
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
June 22, 2025
NCT07451522
NCT07331558
NCT07060937
NCT06726239
NCT06645327
NCT06586749
Lead Sponsor
National University Hospital, Singapore
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions